Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 16/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.40 |
| ▸ | USP2 | O75604 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24960951 | 1.00 | CYP2D6 (0.44) | CYP2D6PIK3CDCYP3A4USP2CYP1A2 | |
| SCHEMBL24961182 | 1.00 | CYP2D6 (0.44) | CYP2D6PIK3CDCYP3A4USP2CYP1A2 | |
| SCHEMBL22924678 | 0.85 | PIK3CD (0.42) | CYP2D6PIK3CDCYP3A4USP2CYP1A2 | |
| SCHEMBL3419567 | 0.81 | CYP2D6 (0.41) | CYP2D6PIK3CDCYP3A4USP2CYP1A2 | |
| SCHEMBL22675449 | 0.79 | FFAR3 (0.44) | FFAR3SMN1; SMN2TSHR | |
| SCHEMBL24134740 | 0.78 | FFAR3 (0.43) | FFAR3 | |
| SCHEMBL23374702 | 0.77 | CYP2D6 (0.43) | CYP2D6PIK3CDCYP3A4USP2CYP1A2 | |
| SCHEMBL21618691 | 0.76 | FFAR3 (0.41) | FFAR3SMN1; SMN2 | |
| SCHEMBL3421104 | 0.74 | CYP2D6 (0.46) | CYP2D6PIK3CDCYP3A4USP2CYP1A2 | |
| SCHEMBL24960892 | 0.73 | CYP2D6 (0.41) | CYP2D6PIK3CDCYP3A4USP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234030-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023006019-A1 | POLYSUBSTITUTED BENZENE PD-L1 INHIBITOR, COMPOSITION AND USE THEREOF | 杭州和正医药有限公司 | 2023-02-02 | — | — | WO | disclosed |
| US-20210024494-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024494-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CYP2D6 3043/4885PIK3CD 2118/4885CYP3A4 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.